Overview · Filed: May 13, 2024
UPC_CFI_146/2024
NOVEL ANTITUMORAL USE OF CABAZITAXEL
InfringementMain Infringement ActionMunich LDInfringementCase Closed
Parties
Claimants
- Sanofi Mature IP(Sanofi Group)
- Sanofi Winthrop Industrie(Sanofi Group)
- Sanofi-Aventis France(Sanofi Group)
- Sanofi-Aventis GmbH(Sanofi Group)
- Sanofi Belgium(Sanofi Group)
- Sanofi-Aventis Deutschland GmbH(Sanofi Group)
- Sanofi S.r.l.(Sanofi Group)
- Sanofi B.V.(Sanofi Group)
- Sanofi - Produtos Farmaceuticos Lda(Sanofi Group)
- Sanofi AB(Sanofi Group)
- Sanofi A/S(Sanofi Group)
Reps: Frédéric Chevallier (McDermott Will & Schulte)
Respondents
- STADAPHARM GmbH
- STADA Arzneimittel AG
- STADA Nordic ApS
Reps: Daniel Hoppe (Bonabry); Christian Meyer (Maiwald Intellectual Property); Anja Lunze (PENTARC Rechtsanwälte)
Judges
- Matthias Zigann
- Alima Zana
- Tobias Pichlmaier
- Carola Wagner
Patents
- EP2493466
CPC codes: A61K38/193, A61K31/573, A61P35/04, A61K31/164, A61K31/56, A61P43/00, A61P13/08, A61P15/00, A61K31/337, A61P35/00, A61K45/06, A61P25/16
Technology area: Pharmaceuticals · Small Molecule
Sector: Pharmaceutical & Medical
Outcome
RevokedDismissed — patent invalid
Filed: May 13, 2024
First decided: Dec 12, 2025
Language: English
The Munich Local Division found patent EP 2 493 466 (relating to cabazitaxel pharmaceutical formulations) invalid for lack of inventive step in infringement proceedings brought by Sanofi against STADA, Dr. Reddy's and Zentiva entities, dismissing the infringement claims.
Open on UPC RegistryClaims
At issue1, 2, 3, 4, 5, 6, 7, 8, 9
Revoked1, 2, 3, 4, 5, 6, 7, 8, 9
Notes: Munich LD revoked EP2493466 (cabazitaxel antitumoral use) in its entirety, claims 1 to 9, for lack of inventive step; infringement actions dismissed.